The effects of resveratrol on glycemic control and cardiometabolic parameters in patients with T2DM: A systematic review and meta-analysis

source extracted confidence: high 2026-04-09
#blood-glucose #cardiovascular-diseases #diabetes-mellitus-type-2 #glycated-hemoglobin #glycemic-control

The effects of resveratrol on glycemic control and cardiometabolic parameters in patients with T2DM: A systematic review and meta-analysis

Abdelhaleem et al., 2022 | Med Clin (Barc) | Meta Analysis

Citation

Abdelhaleem Ibrahim A, Brakat Aml M, ... Aboalfetoh Aya Y. The effects of resveratrol on glycemic control and cardiometabolic parameters in patients with T2DM: A systematic review and meta-analysis. Med Clin (Barc). 2022-Jun-24;158(12):576-585. doi:10.1016/j.medcli.2021.06.028

Abstract

BACKGROUND: Type 2 diabetes mellitus (T2DM) is a progressive meta-inflammatory disorder, which induce micro and macrovascular complications. Resveratrol is a nutraceutical known to have antioxidant and anti-inflammatory properties. It improves insulin resistance; however, no clear evidence regarding its effects in patients with T2DM. OBJECTIVES: We aimed to evaluate the efficacy and the safety of oral resveratrol supplementation in type 2 diabetic patients concerning dose and duration. METHODS: We searched PubMed, Cochrane Library, Scopus, WOS, Wiley, and Google Scholar for RCTs evaluating the efficacy and safety of resveratrol on patients with T2DM. We screened the studies for the eligibility criteria, performed the quality assessment, extracted the studies' characteristics, baseline, and outcome data of interest, and finally conducted the meta-analysis using RevManV5.3. RESULTS: This systematic review and meta-analysis, including 17 RCTs with total 871 patients with T2DM, showed that resveratrol was superior to placebo on fasting blood glucose (FBG) and total cholesterol (TC) with doses ≥500mg {MD=-13.34, 95%CI [-22.73, -3.95], P=0.005}, {MD=-5.64, 95%CI [-6.95, -4.33], P<0.00001} respectively. Moreover, it improved HbA1c at three months {MD=-0.41, 95%CI [-0.65, -0.16], P=0.001 and systolic blood pressure {MD: -7.91, 95%CI [-10.44, -5.37], P<0.00001}. CONCLUSION: We concluded that resveratrol beneficially modulates glycemic control as well as cardiometabolic parameters in patients with T2DM.

Key Findings

This systematic review and meta-analysis, including 17 RCTs with total 871 patients with T2DM, showed that resveratrol was superior to placebo on fasting blood glucose (FBG) and total cholesterol (TC) with doses ≥500mg {MD=-13.34, 95%CI [-22.73, -3.95], P=0.005}, {MD=-5.64, 95%CI [-6.95, -4.33], P<0.00001} respectively. Moreover, it improved HbA1c at three months {MD=-0.41, 95%CI [-0.65, -0.16], P=0.001 and systolic blood pressure {MD: -7.91, 95%CI [-10.44, -5.37], P<0.00001}.

Outcomes Measured

  • blood pressure
  • systolic blood pressure
  • inflammatory markers

Population

Field Value
Population t2dm
Sample Size 871
Age Range See abstract
Condition blood pressure

MeSH Terms

  • Blood Glucose
  • Cardiovascular Diseases
  • Diabetes Mellitus, Type 2
  • Glycated Hemoglobin
  • Glycemic Control
  • Humans
  • Insulin Resistance
  • Resveratrol

Evidence Classification

  • Level: Meta Analysis
  • Publication Types: Journal Article, Meta-Analysis, Systematic Review
  • Vertical: resveratrol

Provenance

Source extracted via PubMed E-utilities API on 2026-04-09